Canuevo is developing drug delivery mechanisms for cannabinoid formulations to increase delivery efficacy. Improving drug delivery is achieved by allowing the body to be exposed to an active compound for long periods of time. Encapsulation agents act as a barrier protecting the active compound and helping it reach its destination.
At Canuevo we design custom vessels for our encapsulated cannabinoids using a variety of biocompatible polymer networks. A mixture of polymer networks can guide the release of an active compound into the body. Depending on the network chosen it can be tuned to withstand low pH and dissolve at higher pH’s. Orally ingested capsules experience a similar change in pH when passing through the gastrointestinal track.
Novel applications for cannabinoids are being discovered everyday. Cannabidiol (CBD) has shown promising effects with management of many neurological disorders such as epilepsy, seizures, movement disorders such as Parkinson’s, Huntington’s, ALS, Alzheimer’s, MS and chronic inflammation. CBD is particularly effective in treating children as it is non-psychoactive and therefore does not produce the “high” generally associated with some cannabinoids.
Ultimately, Canuevo is trying to improve delivery mechanisms for cannabinoids allowing patients to get the medicine they deserve.

CANUEVO IS RUN BY ENTREPRENEURS & SCIENTISTS

Canuevo was started by Nils Rehmann, PhD and Daniel Carbo, MEng. Together the team has a combined experience in drug development of over 15 years and has been working in the cannabis industry around the world.

Nils Rehmann

Nils Rehmann

CEO

PhD in Pharmacology and Toxycology

Daniel Carbo

Daniel Carbo

CSO

Nanosystems Engineer